Search
Famtozinameran
go.drugbank.com/drugs/DB17088ApprovedInvestigationalBA.4, BA.5) which, although similar, may behave differently from one another. … [L43917] Famtozinameran is an mRNA vaccine encoding the S glycoprotein of SARS-CoV-2 Omicron variant lineages BA.4 and BA.5.
Mixtures: Comirnaty Original & Omicron Ba.4/ba.5, Comirnaty Original & Omicron Ba.4/ba.5Chromium
go.drugbank.com/drugs/DB11136ApprovedInvestigationalChromium chloride is available as an intravenous injection for use as a supplement to intravenous solutions given for total parenteral nutrition (TPN) [FDA Label]. … Chromium is a transition element with the chemical symbol Cr and atomic number 24 that belongs to Group 6 of the periodic table.
Mixtures: Extra Once A Day, Maximum Once A DayNemolizumab
go.drugbank.com/drugs/DB15252ApprovedInvestigational[L51159] Nemolizumab gained its first global approval in Japan on March 28, 2022, for the treatment of atopic dermatitis. … [A264274] It was later approved by the FDA on August 13, 2024, for the treatment of prurigo nodularis.[L51169]
Synonyms: Immunoglobulin G2, anti-(interleukin 31 receptor A) (human-Mus musculus monoclonal CIM331 γ-chain), disulfide with human-Mus musculus monoclonal CIM331 κ-chain, dimerDopamine
go.drugbank.com/drugs/DB00988ApprovedInvestigationalDopamine is a major transmitter in the extrapyramidal system of the brain, and important in regulating movement. A family of receptors (receptors, dopamine) mediate its action.
Mixtures: Myocard-DX, Myocard-DXCategories: Monoamine Oxidase A Substrates, Compounds used in a research, industrial, or household settingIopodic acid
go.drugbank.com/drugs/DB09333ApprovedWithdrawnThis drug was approved on March 15, 1962 but it is nowadays discontinued from the FDA and Health Canada. … [A32080] Due to its particular structure, it presents a high degree of lipid solubility and a radiopaque property. It was developed and filed to the FDA by the company BRACCO.
Categories: Compounds used in a research, industrial, or household settingAxicabtagene ciloleucel
go.drugbank.com/drugs/DB13915ApprovedInvestigationalThe drug has a unique mechanism of action, as it utilizes the patient's own T cells, which play a central role in immune response to cancer. … [A216163] Axicabtagene ciloleucel was approved by the FDA on October 18th, 2017.
Bromotheophylline
go.drugbank.com/drugs/DB14018Approved[A33018] Bromotheophylline is categorized on the FDA as a drug substance with an inactive state since March, 1980. … Bromotheophylline is the active moiety of pamabrom, a mixture of 2-amino-2-methyl-propanol and bromotheophylline.
Ponesimod
go.drugbank.com/drugs/DB12016ApprovedInvestigational[A232079] Ponesimod was granted FDA approval on 18 March 2021.[L32709] … [A232079,L32709] Ponesimod was developed out of a need for a more selective modulator of sphingosine 1-phosphate receptor 1 than [fingolimod].
Cupric sulfate
go.drugbank.com/drugs/DB06778ApprovedCupric sulfate is a salt created by treating cupric oxide with sulfuric acid. … practice as a locally applied fungicide, bactericide, and astringent [L1820].
Mixtures: One A Day Advance Adults, One-A-day Advance Men'sCategories: Compounds used in a research, industrial, or household settingParitaprevir
go.drugbank.com/drugs/DB09297ApprovedInvestigationalMore specifically, paritaprevir prevents viral replication by inhibiting the NS3/4A serine protease of Hepatitis C Virus (HCV) [FDA Label]. … Paritaprevir is also available as a fixed-dose combination product with [DB09296] and [DB00503] as the FDA- and Health Canada-approved product Technivie.
Synonyms: ,12Z,13aR,14aR,16aS)-N-(cyclopropanesulfonyl)-6-[(5-methylpyrazine-2-carbonyl)amino]-5,16-dioxo-2-[(phenanthridin-6-yl)oxy]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydrocyclopropa[e]pyrrolo[1,2-a]Categories: NS3/4A Protease Inhibitors, HCV NS3/4A Protease Inhibitors